Patents by Inventor Rubén Álvaro BARTOLOMÉ CONDE

Rubén Álvaro BARTOLOMÉ CONDE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for the treatment of IL13Ra2—overexpressing cancer
    Patent number: 11883416
    Abstract: The invention relates to methods and compositions for treatment of IL13R?2-overexpressing cancer, wherein the treatment comprises administering a protein tyrosine phosphatase-1B (PTP1B) inhibitor.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: January 30, 2024
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)
    Inventors: José Ignacio Casal Álvarez, Rubén Álvaro Bartolomé Conde
  • IL13R?2 peptide and its uses
    Patent number: 11472862
    Abstract: The invention relates to a peptide comprising the amino acid sequence SEQ ID NO: 1 or a variant thereof capable of inhibiting IL13/IL13R?2 signalling. The invention also relates to a fusion protein, nanoparticle, virus-like particle and pharmaceutical composition comprising said peptide, and to their use for treating a cancer characterized by having increased expression of IL13R?2, or for treating asthma, atopic dermatitis or fibrosis, or for preventing the metastatic progression of a cancer characterized by having increased expression of IL13R?2.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 18, 2022
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
    Inventors: Jose Ignacio Casal Alvarez, Rubén Álvaro Bartolomé Conde
  • Methods and compositions for the treatment of IL13Ra2- overexpressing cancer
    Publication number: 20220233552
    Abstract: The invention relates to methods and compositions for treatment of IL13R?2-overexpressing cancer, wherein the treatment comprises administering a protein tyrosine phosphatase-1B (PTP1B) inhibitor.
    Type: Application
    Filed: December 3, 2021
    Publication date: July 28, 2022
    Inventors: José Ignacio CASAL ÁLVAREZ, Rubén Álvaro BARTOLOMÉ CONDE
  • IL13Ra2 PEPTIDE AND ITS USES
    Publication number: 20210363224
    Abstract: The invention relates to a peptide comprising the amino acid sequence SEQ ID NO: 1 or a variant thereof capable of inhibiting IL13/IL13R?2 signalling. The invention also relates to a fusion protein, nanoparticle, virus-like particle and pharmaceutical composition comprising said peptide, and to their use for treating a cancer characterized by having increased expression of IL13R?2, or for treating asthma, atopic dermatitis or fibrosis, or for preventing the metastatic progression of a cancer characterized by having increased expression of IL13R?2.
    Type: Application
    Filed: November 5, 2018
    Publication date: November 25, 2021
    Inventors: Jose Ignacio CASAL ALVAREZ, Rubén Álvaro BARTOLOMÉ CONDE
  • Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 RGD motif
    Patent number: 10829560
    Abstract: The disclosure relates to agents binding specifically to human cadherin 17 (CDH17), and/or to human cadherin 5 (CDH5), and/or to human cadherin 6 (CDH6), and/or to human cadherin 20 (CDH20). The disclosure also relates to the use of these agents in therapy, methods for diagnosis and/or prognosis and/or stratification of a cancer in a subject, and pharmaceutical compositions comprising said agents. The disclosure also relates to cancer markers and markers of metastasis.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: November 10, 2020
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: José Ignacio Casal Álvarez, Rubén Álvaro Bartolome Conde
  • AGENTS BINDING SPECIFICALLY TO HUMAN CADHERIN-17, HUMAN CADHERIN-5, HUMAN CADHERIN-6 AND HUMAN CADHERIN-20 RGD MOTIF
    Publication number: 20190048090
    Abstract: The disclosure relates to agents binding specifically to human cadherin 17 (CDH17), and/or to human cadherin 5 (CDH5), and/or to human cadherin 6 (CDH6), and/or to human cadherin 20 (CDH2O). The disclosure also relates to the use of these agents in therapy, methods for diagnosis and/or prognosis and/or stratification of a cancer in a subject, and pharmaceutical compositions comprising said agents. The disclosure also relates to cancer markers and markers of metastasis.
    Type: Application
    Filed: April 20, 2015
    Publication date: February 14, 2019
    Inventors: José Ignacio CASAL ÁLVAREZ, Rubén Álvaro BARTOLOME CONDE